| Literature DB >> 21729301 |
Amir Y Tashakkor1, Katherine S Chow, Chris Carlsten.
Abstract
BACKGROUND: Outdoor air pollution, given its demonstrated negative effects on the respiratory system, is a growing public health concern worldwide, particularly in urban cities. Human exposure to pollutants such as ozone, nitrogen oxides, combustion-related particulate matter and oxides of sulfur is responsible for significant cardiopulmonary morbidity and mortality in both adults and children. Several antioxidants have shown an ability to partially attenuate the negative physiological and functional impacts of air pollutants. This study systematically presents current data on the potential benefits of antioxidant supplementation on lung function outcomes associated with air pollutant exposures in intact humans.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21729301 PMCID: PMC3158771 DOI: 10.1186/1471-2458-11-532
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Figure 1Flow chart of included studies.
Studies assessing effect of antioxidant supplementation on lung function associated with air pollutant exposures in intact humans
| First author, Year, Country | Study design | Conditions* | Pollutant exposure duration | Additional stresses during exposure | Population | Age range | Inclusion / Exclusion criteria | Outcome |
|---|---|---|---|---|---|---|---|---|
| Randomized | a) 800 IU Vitamin E (9 to 10 weeks); air then next-day ozone (0.5 ppm) | 2 hr | Heat and "light exercise" | Healthy | 20-27 | Not Specified. | No significant effect of antioxidants on ozone-attributable decrease in FEV1 and FVC. (i.e. statistical significance of supplementation effect: p > 0.05). | |
| b) Placebo (9 to 10 weeks);air then next day ozone (0.5 ppm) | ||||||||
| Randomized | a) 1600 IU Vitamin E (11 to 12 weeks); air then ozone (0.5 ppm, for 2 subsequent days) | 2 hr | Heat and "light exercise" | Healthy males | 22-28 | Not Specified. | No significant effect of antioxidants on ozone-attributable decrease in FEV1, FVC, TLC, FEF25%, FEF50% (i.e. statistical significance of supplementation effect: p > 0.05). | |
| b) Placebo (11 to 12 weeks); air | ||||||||
| Randomized (crossover); double-blinded | a) Vitamin C (1 gm, one hour before exposure) and Vitamin E (800 IU daily for unspecified duration); ozone (0.3 ppm) | 2 hr | Exercise | Medical students | 21-29 | Normal baseline pulmonary function, non-smokers, refrained from any drugs, including vitamin supplements. | Ozone-induced decrements in FVC were attenuated by vitamin C and vitamin E (p < 0.05), but no significant effect was observed in FEV1, FEF25-75 and SGaw (p > 0.05). | |
| b) Placebo; Ozone (0.3 ppm) | ||||||||
| Randomized (crossover); double-blinded | a) Vitamin C (2000 mg/day for 3 days); NO2 (2.0 ppm) | 1 hr | Healthy subjects | 18-36 | Not Specified. | Airway hypersensitivity induced by NO2 was attenuated by pre-treatment with ascorbic acid, relative to placebo (p < 0.04). | ||
| b) Placebo (3 days); NO2 (2.0 ppm) | ||||||||
| c) Vitamin C (2000 mg/day for 3 days); air | ||||||||
| d) Placebo; air | ||||||||
| Double-blinded; | a) Placebo; ozone (0.4 ppm) | 2 hr | Intermittent exercise | Mild atopic asthmatics | 19-26 | Required a measurable plateau of the dose-response curve to methacholine, non smokers, no NSAID or vitamin use during study. | Airway hypersensitivity induced by O3 was attenuated by pre-treatment with apocynin, relative to placebo (p = 0.025). | |
| b) Apocynin (12 mg); ozone (0.4 ppm) | ||||||||
| Randomized | a) Vitamin C-restricted diet + placebo (2 weeks); ozone (0.4 ppm) | 2 hr | Exercise | Healthy on a low ascorbate diet | 18-35 | Non-smokers. | Ozone-induced decrements in FEV1 and FVC were attenuated (p = 0.046 and p = 0.055 respectively), by vitamin C and vitamin E. | |
| b) Vitamin C-restricted diet + | ||||||||
| c) Vitamin C-restricted diet | ||||||||
| Randomized (crossover); | a) Placebo; ozone (0.12 ppm) | 45 min | Intermittent exercise | Adults with asthma | 18-39 | Significant decrease (at least 8%) in FVC1 from baseline with SO2 challenge, non-smokers. | SO2-induced decrements in FEV1 and peak expiratory flow (PEF), and FEF25-75 were attenuated by vitamin C and vitamin E (p < 0.05). | |
| b) 400 IU vitamin E and 500 mg | ||||||||
| c) Placebo; air | ||||||||
| d) 400 IU Vitamin E and 500 mg Vitamin C daily (4 weeks); air | ||||||||
| Randomized (crossover); | a) Placebo; ozone (0.2 ppm) | 2 hr | Intermittent exercise | Healthy ozone-sensitive | 21-27 | Normal lung function, negative skin prick test, non-smokers, no history of allergy and/or lung disease. | No significant effect of antioxidants on ozone-attributable decrease in FEV1 (p > 0.05). | |
| b) 500 mg | ||||||||
| c) air |
* For crossover studies, each individual subjected to each condition; in non-crossover, the conditions were distributed between subjects.
Studies assessing effect of antioxidant supplementation on lung function associated with air pollutant exposures in intact humans
| First author, Year, Country | Study design | Conditions* | Pollutant exposure duration | Anti-oxidant (dose) and duration | Population | Age range | Inclusion/Exclusion criteria | Outcome |
|---|---|---|---|---|---|---|---|---|
| Randomized (crossover); double-blinded | a) Placebo; 24-Hour average [pollutant]: SO2 142-159 (mcg/mol), total particulate 322-453 (mcg/mol), CO2 1.5-4.8 (ppm), NO2 139-178 (mcg/mol) | 2 hours in 'acute' protocol; 4 days in 'chronic' protocol | Vitamin C (2 gm) once in 'acute' protocol and vitamin C (2 gm/day) for 4 days in 'chronic' protocol | Policemen | 24-37 | Normal lung function tests, no history of asthma, respiratory tract infection in the six weeks preceding the study. | Pollutant-induced decrement in PC25MEF50 (airway reactivity) attenuated by vitamin C. in 'acute' protocol; Pollutant-induced decrement in PC25MEF50 attenuated by vitamin C in 'chronic' protocol (p < 0.001). Peak expiratory flow decrements also significantly attenuated by vitamin C (but p-value not reported). | |
| b)Anti-oxidant; 24-Hour average [pollutant]: SO2 142-159 (mcg/mol), Total particulate 322-453 (mcg/mol), CO2 1.5-4.8 (ppm), NO2 139-178 (mcg/mol) | ||||||||
| Randomized | a) Placebo; 8-Hour average [ozone]: 101 (μg/m3) | 70 days | Vitamin E (75 mg/day), Vitamin C (650 mg/day) and β-carotene (15 mg/day) for 3 months | Amateur cyclists | 16-41 | Subjects with a range in exposure to ozone of less than 50 (μg/m3) were excluded for analysis. | Ozone-associated decrements in FVC, FEV1, and peak expiratory flow (PEF), were attenuated by vitamin E, vitamin C and β-carotene. No p-value provided. | |
| b)Anti-oxidant; 8-Hour average [ozone]: 101 (μg/m3) | ||||||||
| Randomized (crossover); double-blinded | a) Placebo; hourly average [pollutant]: ozone 67.3 (ppb), NO2 52.3 (ppb), PM10 76.5 (μg/m3) with placebo | 6 months | Vitamin E (75 mg/day), Vitamin C (650 mg/day) and β-carotene (15 mg/day) for 130 days over 2 phases | Male street workers | 18-58 | Working outdoors in the central area of Mexico City, No more than 5 cigarettes/day. | Ozone-associated decrease in FEV1, FVC and FEF25-75 attenuated by Vitamin C, Vitamin E and βeta-carotene. (first phase of study p values for all 3 parameters: p < 0.01; second phase of study p values for FVC and FEF25-75 p < 0.01 and p < 0.05 for FEV1). | |
| b)Anti-oxidant; hourly average | ||||||||
| Randomized (non-cross over); double-blinded | a)Placebo; 8-Hour average [ozone]: 84-88 (μg/m3) | 15 weeks | Vitamin E (100 mg/daily), Vitamin C (500 mg/daily) for 15 weeks | Amateur and recreational cyclists | 17-58 | Non smokers. | Ozone-associated decrease in FEV1, FVC attenuated by Vitamin C, and Vitamin E (p < 0.05). | |
| b)Anti-oxidant; 8-Hour average [ozone]: 84-88 (μg/m3) | ||||||||
| Randomized; double-blinded | a) Placebo; 24-Hour average [pollutant]: SO2 33 (ppb), PM10 56.68 (μg/m3), NO2 30 (μg/m3) ozone 32 (ppb) | 12 weeks | Vitamin E (50 mg/day), Vitamin C (250 mg/day) for 12 weeks | Asthmatic children | 6-17 | Not specified. | Ozone-associated decrements in FEF25-75 and PEF were attenuated by vitamin E and vitamin C (p < 0.05). | |
| b)Anti-oxidant; 24-Hour average |
* For crossover studies, each individual subjected to each condition; in non-crossover, the conditions were distributed between subjects.